Zydus, MSN partner to license and supply Cabozantinib Tablets for the US
May 20, 2024
Source: drugdu
145
Zydus Lifesciences announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE has entered into an exclusive licensing and supply agreement with MSN Laboratories for Cabozantinib Tablets (a generic version of CABOMETYX) for the US market.
As per the terms of the agreement, MSN Laboratories will be in charge of manufacturing and supplying the generic version of CABOMETYX, following the receipt of regulatory approval. Zydus will exclusively market, distribute, and sell the product in the US market. MSN was the first sole ANDA applicant for Cabozantinib Tablets, to submit a substantially complete ANDA with a paragraph IV certification and therefore may be eligible for 180 days of generic drug exclusivity for the generic version of CABOMETYX.
The total addressable market opportunity of Cabozantinib Tablets in the US is approximately $ 1,464 million.
https://ir.exelixis.com/news-releases/news-release-details/exelixis-and-ipsen-enter-exclusive-licensing-agreement
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- Taking advantage of the “Eight Measures of Science and Technology”, Haier Health aims to create a flagship of biotechnology December 24, 2024
- Beware of “two sets of prices” providing funding sources for pharmaceutical bribery December 24, 2024
- Is placebo effective? Vertex evaporates $13 billion overnight December 24, 2024
- Aadi Biosciences and WuXi Biologics collaborate to develop 3 new ADC drugs December 24, 2024
- Novo Nordisk’s talent war December 24, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
